From In Silico Design to In Vitro Impact
Artificial intelligence is transforming molecular design, but synthesis remains the limiting step in drug discovery. To translate computational advances into real productivity gains, organizations must better align digital design with laboratory execution. AI-driven orchestration provides a practical framework to coordinate design, synthesis, and testing within existing R&D infrastructures, accelerating the transition from in silico hypotheses to in vitro validation and improving the productivity of the DMTA cycle.
To read the full article, please follow this link.
